RDEA3170 and Febuxostat Drug Interaction Study

Inclusion Criteria: * body weight ≥ 50 kg (110 lbs.) and a body mass index ≥ 18 and ≤ 40 kg/m2. * no clinically relevant abnormalities in vital signs, ECG, physical examination or safety laboratory values, per the Investigator's judgment. * a screening serum urate level ≥ 4.5 mg/dL. Exclusion Criteria: * history or suspicion of kidney stones. * history of cardiac abnormalities as assessed during screening, including abnormal and clinically relevant electrocardiogram changes and/or family history of sudden death in otherwise healthy individual between the ages of 1 and 30 years. * undergone major surgery within 3 months prior to Day 1. * donated blood or experienced significant blood loss (\> 450 mL) within 12 weeks prior to Day 1 or gave a plasma donation within 4 weeks prior to the Screening Period. * inadequate venous access or unsuitable veins for repeated venipuncture.